Literature DB >> 7850315

Percutaneous cryosurgery for renal tumours.

M Uchida1, Y Imaide, K Sugimoto, H Uehara, H Watanabe.   

Abstract

OBJECTIVE: To evaluate the use of percutaneous cryosurgery in the treatment of renal tumours.
MATERIALS AND METHODS: A cryoprobe using liquid nitrogen was designed. The tolerance of renal cancer cells to cooling was tested. Freezing tests on two extirpated kidneys involved with hypervascular tumour were performed in water at 40 degrees C. A clinical trial of percutaneous cryosurgery was carried out in two patients with advanced renal carcinoma.
RESULTS: The cooling function of the new probe was similar to that of a conventional probe. The tolerance test on renal cancer cells showed that the cooling temperature should be below -20 degrees C to render them necrotic. Freezing tests on two nephrectomized kidneys with hypervascular renal cancer suggested that embolization of the renal artery might be advisable before treatment. The clinical trial in two patients with advanced renal carcinoma showed that the whole kidney, including the tumour, became necrotic and shrunken post-operatively. The patients' Karnofsky performance scale showed a marked improvement 3 months after the operation, but their general condition gradually deteriorated. Patient 1 died 10 months and patient 2 died 5 months after the procedure.
CONCLUSION: Percutaneous cryosurgery was performed successfully in two patients with hypervascular renal tumours. Cryo-immunological activity was assumed to have contributed to the temporary improvement in their condition. These results suggest that percutaneous cryosurgery might be useful as minimally invasive treatment in a limited number of patients with advanced renal carcinoma.

Entities:  

Mesh:

Year:  1995        PMID: 7850315     DOI: 10.1111/j.1464-410x.1995.tb07297.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  33 in total

1.  [Renal cell carcinoma].

Authors:  A Haferkamp; D Rohde; S C Müller; H Rübben; M Hohenfellner
Journal:  Urologe A       Date:  2006-09       Impact factor: 0.639

2.  Renal function and oncologic outcomes after cryoablation or partial nephrectomy for tumors in solitary kidneys.

Authors:  Jatinder Goyal; Abhinav Sidana; Christos S Georgiades; Ronald Rodriguez
Journal:  Korean J Urol       Date:  2011-06-17

Review 3.  Percutaneous MR-guided cryoablation for malignancies, with a focus on renal cell carcinoma.

Authors:  Takuji Mogami; Junta Harada; Kouichi Kishimoto; Sajio Sumida
Journal:  Int J Clin Oncol       Date:  2007-04-27       Impact factor: 3.402

4.  Saline Mobilization of the Colon during Percutaneous Renal Cryoablation.

Authors:  Anthony J Polcari; Marc A Borge; Kent T Perry
Journal:  Semin Intervent Radiol       Date:  2007-09       Impact factor: 1.513

5.  Methods for characterizing convective cryoprobe heat transfer in ultrasound gel phantoms.

Authors:  Michael L Etheridge; Jeunghwan Choi; Satish Ramadhyani; John C Bischof
Journal:  J Biomech Eng       Date:  2013-02       Impact factor: 2.097

Review 6.  Renal ablation update.

Authors:  Vishal Khiatani; Robert G Dixon
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

Review 7.  Update on cryoablation for treatment of small renal mass: oncologic control, renal function preservation, and rate of complications.

Authors:  Anil Kapoor; Yuding Wang; Brad Dishan; Stephen E Pautler
Journal:  Curr Urol Rep       Date:  2014-04       Impact factor: 3.092

8.  Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis.

Authors:  David A Kunkle; Robert G Uzzo
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

9.  The impact of renal tumor size on the efficacy of laparoscopic renal cryoablation.

Authors:  Byeong Kuk Ham; Sung Gu Kang; Hoon Choi; Young Hwii Ko; Seok Ho Kang; Jun Cheon
Journal:  Korean J Urol       Date:  2010-03-19

10.  Current status of ablative therapies for renal tumors.

Authors:  Adam C Mues; Jaime Landman
Journal:  Indian J Urol       Date:  2009 Oct-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.